NewAmsterdam Pharma (NASDAQ:NAMS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.48) by 8.33 percent. This is a 246.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $3.701 million which beat the analyst consensus estimate of $1.663 million by 122.57 percent. This is a 80.67 percent decrease over sales of $19.145 million the same period last year.